Tonix Pharmaceuticals Appoints Jessica Morris as Chief Operating Officer
January 09 2018 - 7:00AM
Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), a
company developing innovative pharmaceutical and biological
products to address major public health challenges, today announced
the appointment of Jessica Morris as Chief Operating Officer.
Previously Executive Vice President of Operations, Ms. Morris
brings to the senior leadership team a deep understanding of drug
development and corporate strategy from her tenure at Tonix as well
as over a decade of experience in the financial industry.
“Ms. Morris’ contributions have been integral to Tonix as we
have advanced and expanded our pipeline,” commented Seth Lederman,
M.D., President and Chief Executive Officer of Tonix. “With the
increased responsibility of this new role, Ms. Morris will perform
key management functions in ensuring efficient advancement of our
late-stage candidate, Tonmya®*, for which we expect to report
topline data from the Phase 3 HONOR study in military-related PTSD
in the fourth quarter of this year.”
Ms. Morris has served in positions of increasing responsibility
at Tonix beginning in 2013. Prior to joining Tonix, Ms. Morris
served in an investment management role at Zhong Rong Group, as
well as at American Capital and Calvert Street Capital
Partners. In addition, Ms. Morris worked in banking at
Silicon Valley Bank and Deutsche Bank. Ms. Morris holds degrees in
commerce and music from the University of Virginia, where she was
an Echols Scholar.
*Tonmya has been conditionally accepted by the U.S. Food and
Drug Administration (FDA) as the proposed trade name for TNX-102 SL
(cyclobenzaprine HCl sublingual tablets) for PTSD. TNX-102 SL is an
investigational new drug and has not been approved for any
indication.
About Tonix Pharmaceuticals Holding Corp.
Tonix is developing innovative pharmaceutical and biological
products to address major public health challenges and diseases
with significant unmet needs. Tonix’s lead product candidate,
Tonmya, or TNX-102 SL, is in Phase 3 development as a bedtime
treatment for PTSD. Due to the unique mechanism of action of the
active ingredient (TNX-102 or cyclobenzaprine hydrochloride) in
Tonmya to improve sleep quality, TNX-102 SL is being developed as a
bedtime treatment for agitation in Alzheimer’s disease. Tonix is
planning to submit an IND for this additional indication in 1Q2018
after completing a successful pre-IND meeting with the FDA in
4Q2017. TNX-601 (tianeptine oxalate) is in the pre-IND
(Investigational New Drug) application stage, also for the
treatment of PTSD but designed for daytime dosing. Tonix’s lead
biologic candidate, TNX-801, is a potential smallpox-preventing
vaccine based on a live synthetic version of horsepox virus,
currently in the pre-IND application stage.
This press release and further information about Tonix can be
found at www.tonixpharma.com.
Forward Looking Statements
Certain statements in this press release are forward-looking
within the meaning of the Private Securities Litigation Reform Act
of 1995. These statements may be identified by the use of
forward-looking words such as “anticipate,” “believe,” “forecast,”
“estimate,” “expect,” and “intend,” among others. These
forward-looking statements are based on Tonix's current
expectations and actual results could differ materially. There are
a number of factors that could cause actual events to differ
materially from those indicated by such forward-looking statements.
These factors include, but are not limited to, substantial
competition; our need for additional financing; uncertainties of
patent protection and litigation; uncertainties of government or
third party payor reimbursement; limited research and development
efforts and dependence upon third parties; and risks related to
failure to obtain FDA clearances or approvals and noncompliance
with FDA regulations. As with any pharmaceutical under development,
there are significant risks in the development, regulatory approval
and commercialization of new products. Tonix does not undertake an
obligation to update or revise any forward-looking statement.
Investors should read the risk factors set forth in the Annual
Report on Form 10-K for the year ended December 31, 2016, as filed
with the Securities and Exchange Commission (the “SEC”) on April
13, 2017, and periodic reports filed with the SEC on or after the
date thereof. All of Tonix's forward-looking statements are
expressly qualified by all such risk factors and other cautionary
statements. The information set forth herein speaks only as of the
date thereof.
Contacts
Jessica Morris (investors)Tonix
Pharmaceuticalsinvestor.relations@tonixpharma.com(212) 980-9159
Rich Allan (media)Russo
Partnersrich.allan@russopartnersllc.com(646) 942-5588
Tonix Pharmaceuticals (NASDAQ:TNXP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Tonix Pharmaceuticals (NASDAQ:TNXP)
Historical Stock Chart
From Sep 2023 to Sep 2024